Ann: Mente Pro Update, page-16

There is a fair amount of preliminary data out there already, enough to warrant a speculative investment in Neurotech IMO.

And when looking around the ASX, NTI has more early stage validation than many stocks.

Dr Attared Trevisan has published studies and papers on Mente. And there are medical papers showing the efficacy of neurofeedback as a treatment for ASD.

Neurotech's pilot study was successful and illustrated significant improvement in patients EEG profile, behavioural improvements and improved communication.

2 independent user studies were also done that enabled the Italian Distribution Agreement (obligation to purshase min 8,700 units...)

We then have CE Marking certification that classifies Mente as a medical device in the EU. And the company also has a few listings under FDA already.

ISO certified as well.

Double blind & independent US clinical trial underway. Undertaken in conjunction with Carrick (look them up) with results expected in Q2.

The preliminary data and milestones achieved highlight the US trails have a good change of being positive IMO.